BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32462913)

  • 1. Can a biomarker triage test reduce colonoscopy burden in fecal immunochemical test screening?
    Greuter MJ; Carvalho B; Wit M; Dekker E; Spaander MC; Meijer GA; Engeland MV; Coupé VM
    J Comp Eff Res; 2020 Jun; 9(8):563-571. PubMed ID: 32462913
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
    Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
    Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening.
    Bronzwaer MES; Greuter MJE; Bleijenberg AGC; IJspeert JEG; Dekker E; Coupé VMH
    BMC Cancer; 2018 Apr; 18(1):465. PubMed ID: 29695244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Screening for Colorectal Cancer: An Algorithm Combining Fecal Immunochemical Test, Blood-Based Cancer-Associated Proteins and Demographics to Reduce Colonoscopy Burden.
    Petersen MM; Kleif J; Jørgensen LN; Hendel JW; Seidelin JB; Madsen MR; Vilandt J; Brandsborg S; Rasmussen JS; Andersen LM; Khalid A; Ferm L; Gawel SH; Martens F; Andersen B; Rasmussen M; Davis GJ; Christensen IJ; Therkildsen C
    Clin Colorectal Cancer; 2023 Jun; 22(2):199-210. PubMed ID: 36878807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.
    Toes-Zoutendijk E; van Leerdam ME; Dekker E; van Hees F; Penning C; Nagtegaal I; van der Meulen MP; van Vuuren AJ; Kuipers EJ; Bonfrer JMG; Biermann K; Thomeer MGJ; van Veldhuizen H; Kroep S; van Ballegooijen M; Meijer GA; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I;
    Gastroenterology; 2017 Mar; 152(4):767-775.e2. PubMed ID: 27890769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short Term Outcomes of Using Fecal Immunochemical Test for a Pilot Colorectal Cancer Screening Program. A Single Center Study on 3024 Consecutive Patients.
    Constantin A; Cazacu I; Ciocârlan M; Constantinescu C; Baltog G; Balahura C; Doraş I; Filip S; Filip G; Panazan I; Piţigoi D; Pirvu V; Turcu F; Copăescu C; Săftoiu A
    Chirurgia (Bucur); 2020; 115(4):448-457. PubMed ID: 32876018
    [No Abstract]   [Full Text] [Related]  

  • 10. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
    Caviglia GP; Cabianca L; Fagoonee S; Gili FM
    Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological biomarkers in triage of FIT-positive subjects?
    Nielsen HJ; Christensen IJ; Andersen B; Rasmussen M; Friis-Hansen LJ; Bygott T; MiCallef J;
    Scand J Gastroenterol; 2017; 52(6-7):742-744. PubMed ID: 28271924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interval post-colonoscopy colorectal cancer following a negative colonoscopy in a fecal immunochemical test-based screening program.
    van de Schootbrugge-Vandermeer HJ; Kooyker AI; Wisse PHA; Nagtegaal ID; Geuzinge HA; Toes-Zoutendijk E; de Jonge L; Breekveldt ECH; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Lansdorp-Vogelaar I; Spaander MCW; van Leerdam ME
    Endoscopy; 2023 Dec; 55(12):1061-1069. PubMed ID: 37793423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population.
    Malagón M; Ramió-Pujol S; Serrano M; Amoedo J; Oliver L; Bahí A; Miquel-Cusachs JO; Ramirez M; Queralt-Moles X; Gilabert P; Saló J; Guardiola J; Piñol V; Serra-Pagès M; Castells A; Aldeguer X; Garcia-Gil LJ
    PLoS One; 2020; 15(12):e0243158. PubMed ID: 33259546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlating Quantitative Fecal Immunochemical Test Results with Neoplastic Findings on Colonoscopy in a Population-Based Colorectal Cancer Screening Program: A Prospective Study.
    Shahidi N; Gentile L; Gondara L; Hamm J; McGahan CE; Enns R; Telford J
    Can J Gastroenterol Hepatol; 2016; 2016():4650471. PubMed ID: 28116286
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of screening using annual fecal immunochemical test alone versus combined with one-time colonoscopy in reducing colorectal cancer mortality: the Akita Japan population-based colonoscopy screening trial (Akita pop-colon trial).
    Saito H; Kudo SE; Takahashi N; Yamamoto S; Kodama K; Nagata K; Mizota Y; Ishida F; Ohashi Y
    Int J Colorectal Dis; 2020 May; 35(5):933-939. PubMed ID: 32034490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Validation of a Multitarget Fecal Immunochemical Test for Colorectal Cancer Screening : A Diagnostic Test Accuracy Study.
    de Klaver W; Wisse PHA; van Wifferen F; Bosch LJW; Jimenez CR; van der Hulst RWM; Fijneman RJA; Kuipers EJ; Greuter MJE; Carvalho B; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    Ann Intern Med; 2021 Sep; 174(9):1224-1231. PubMed ID: 34280333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.